Flu Lab
Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, supported travel scholarships for this 8th AVG/3rd IMRP Meeting.
Thank you to our IMRP and AVG sponsors and contributors
Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, supported travel scholarships for this 8th AVG/3rd IMRP Meeting.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Shionogi & Co., Ltd., is a 147-year-old global pharmaceutical company with headquarters in Osaka, Japan and offices around the world. Globally, Shionogi leverages our science-based heritage to develop and commercialize pharmaceutical products that address unmet medical needs in infectious disease, as well as other areas of high medical need, including neurology and cardiovascular disease.
Cidara Therapeutics (Nasdaq: CDTX) is a clinical-stage biotechnology company pioneering a new class of targeted immunotherapies known as drug-Fc conjugates (DFCs). Built on the company’s proprietary Cloudbreak® platform, DFCs uniquely combine the potency and specificity of small molecules with the durability of monoclonal antibodies, creating a “single-molecule cocktail” with improved potency and safety.
Cidara’s lead program, CD388, is a first-in-class, long-acting antiviral DFC in development for universal influenza prophylaxis. Designed to provide season-long protection against both influenza A and B with a single injection, CD388 has the potential to fundamentally reshape the prevention landscape. Importantly, as CD388 is a long-acting antiviral drug, and not a vaccine, it can provide single-dose, universal protection against all stains of influenza in high-risk and immune compromised individuals regardless of their immune status.
In June 2025, results from the Phase 2b NAVIGATE trial of CD388 demonstrated robust efficacy, with up to 76% protection against influenza over 24 weeks, alongside a favorable safety profile comparable to placebo. Based on these data, Cidara has submitted an End-of-Phase-2 meeting request to the FDA to discuss the details of the Phase 3 development plan.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.
16 September
This workshop will provide an introduction to GISAID’s databases and tool ecosystem, with live demonstrations. Participants will explore applications in genomic epidemiology, phylogenetics, and practical tools such as EpiCharts, Primer Checker, BLAST, and AudacityInstant. The session is designed to give hands-on insights into how GISAID supports global pathogen surveillance and public health response.
